Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs

Mostrar otras versiones (1)

Remdesivir (RDV; GS-5734) is currently the only FDA-approved antiviral drug for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The drug is approved for use in adults or children 12 years or older who are hospitalized for the treatment of COVID-19 on the basi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schooley, Robert T., Carlin, Aaron F., Beadle, James R., Valiaeva, Nadejda, Zhang, Xing-Quan, Clark, Alex E., McMillan, Rachel E., Leibel, Sandra L., McVicar, Rachael N., Xie, Jialei, Garretson, Aaron F., Smith, Victoria I., Murphy, Joyce, Hostetler, Karl Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448143/
https://www.ncbi.nlm.nih.gov/pubmed/34310217
http://dx.doi.org/10.1128/AAC.01155-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448143/
https://www.ncbi.nlm.nih.gov/pubmed/34310217
http://dx.doi.org/10.1128/AAC.01155-21

Ejemplares similares